MedTrace Logo

Accurate Staging of Immuno-virological Dynamics During Acute HIV Infection

NCT03449706 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2025-01-14

No results posted yet for this study

Summary

In this prospective longitudinal study we aim to assess how immunologic and viral aspects of the human immunodeficiency virus (HIV) viral reservoir, established during early HIV infection and responsible for viral rebound at treatment interruption, evolve in individuals who start combination anti-retroviral therapy (cART) during acute seroconversion.

Recently infected patients will be selected based on Fiebig staging for an in depth sampling protocol at different timepoints during a 2 year follow up period. Colonbiopsies, lymphnode resection, lumbar puncture, leucapheresis and repeated peripheral venous blood-draws will be performed. Immunological, virological and genome expression analysis will be performed on the gathered samples.

Conditions

  • HIV
  • Seroconversion, HIV

Interventions

DRUG

Early combination anti-retroviral treatment

Patients are started on treatment to supress the HIV virus in the phase of acute seroconversion.

Sponsors & Collaborators

  • ViiV Healthcare

    collaborator INDUSTRY

  • University Hospital, Ghent

    lead OTHER

Principal Investigators

  • Linos Vandekerckhove, Prof. Dr. · University Hospital, Ghent

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-01
Primary Completion
2028-01-01
Completion
2028-01-01

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03449706 on ClinicalTrials.gov